Opinion|Videos|June 2, 2025
Equitable Access to Molecular Testing and Treatment Prioritization
Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.
Advertisement
Episodes in this series
Molecular Testing and Biomarker Considerations
Key Themes:
- Barriers to equitable access for comprehensive molecular testing
- Strategies to overcome testing barriers
- Treatment prioritization when ALK+ status coexists with other actionable biomarkers
Notable Insights:
- Dr Dietrich identified barriers to comprehensive molecular testing including NGS
- Grizzard offered suggestions for clinicians to overcome testing barriers
Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
CMS Proposes Nearly Flat 2027 Medicare Advantage Payment Rates
2
ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care
3
FAQ: What to Know About the Vaccine Rollbacks and What They Mean Long-Term
4
Ambient AI Tool Adoption in US Hospitals and Associated Factors
5
